News

WuXi teams up with Foundation Medicine to bring cancer profiling to China

WuXi PharmaTech has struck a deal with the genomics experts at Foundation Medicine, signing on to offer the company's cancer-decoding services to drug developers in its native China.

Icon posts another revenue jump and dials up its expectations

CRO giant Icon charted double-digit revenue growth in the third quarter, chugging toward its best-ever year and lifting its earnings projections in the process.

Big CROs are booming, but can it last?

The world's largest CROs are reaping the benefits of two major market trends: Big Pharma is finally getting back to spending big on R&D after some lean years post-downturn, and biotech is enjoying a protracted bit of bullishness that has lined pockets around the industry.

Charles River debuts new testing tech for quality control

Charles River Laboratories has unveiled a new technology it says can better test for impurities by combining two common methods into a single product, making for a flexible solution.

A glitch in bioequivalence software puts trial results in doubt

Observed glitches with Thermo Fisher's popular drug development software have led to concerns that data used to win approvals may have been faulty, and the company is working alongside regulators to figure out just how widespread the issue may be.

Roche taps DKSH to move its products in Asia

DKSH, a well-heeled pharma marketing operation, has reupped with Roche, expanding a long-standing agreement to include more of Asia.

PPD pairs off with Sellas to pick up the pipeline pace

PPD has signed a master service agreement with Swiss biotech Sellas, lending its drug development expertise to the company's efforts to advance a portfolio of treatments.

INC signs on to help Provectus get its regulatory act together

Provectus Biopharmaceuticals, a biotech that has been stung by regulatory setbacks, has recruited INC Research to audit its data on two drug candidates, tasking the CRO with poring over its documents as it moves into late-stage development.

Catalent reaches out to lung cancer patients with research agreement

Catalent has partnered with the Lung Cancer Alliance to survey patients on how they manage the disease and deal with treatment compliance, an effort to highlight unmet needs and match them with new dosage forms.

Covance and Novartis team up with eyes on Big Data

Covance has joined forces with Novartis to develop new ways to help drug developers quickly integrate and analyze huge swaths of study data.

Parexel expands in the U.K. after an eClinical buyout

Parexel International is widening its presence in Nottingham, U.K., tapping local grant funds to consolidate some outposts with plans to grow around its latest acquisition.

Clinipace raises $4M after staging 5 buyouts in 5 years

North Carolina CRO Clinipace has raised $4 million, and while the company isn't disclosing why it needs the cash, the move follows years of dealmaking and could be a prelude to another buyout.

With help from Charles River, AstraZeneca expands its respiratory pipeline

AstraZeneca is moving forward with a respiratory candidate developed alongside Charles River Laboratories' discovery business, a milestone the CRO says affirms its investments in the space.

European CRO Genae stretches out in the U.S.

Belgian researcher Genae has expanded its U.S. presence with an office in New York City, part of its strategy to capitalize on the North American market for clinical trials.

Accelovance poaches a Big Pharma vet to lead its oncology efforts

Early-phase CRO Accelovance has landed a former Pfizer and Otsuka exec to flesh out its efforts in oncology, part of a sweeping growth strategy that has seen the company expand across the U.S.

Chiltern picks up an Asian CRO with eyes on oncology

CRO Chiltern has reached into Singapore for its latest acquisition, buying out an Asian clinical contractor to expand its geographic footprint and therapeutic reach.

Catalent bets on armed antibodies with Redwood buyout

In its first acquisition since going public over the summer, Catalent has bought up longtime partner Redwood Bioscience, bringing in proprietary technology for developing antibody-drug conjugates.

WuXi snags a stateside CRO to beef up its early-stage services

Chinese CRO WuXi PharmaTech has bought out XenoBiotic Laboratories, a U.S. contractor focused on early-phase research, expanding its North American presence and broadening its lab-based business.

Parexel buys a U.K. tech outfit to expand its eClinical biz

Parexel International has bought up the U.K.'s ClinIntel, a supply chain software outfit that should fit right in with the CRO's growing technology business.

AstraZeneca moves away from outsourcing, at least in IT

AstraZeneca is looking to bring more of its IT work in-house, spending money to stand up an Indian hub that will replace much of its contract spend in the field.